Top Markets
Coin of the day
Organicell Regenerative Medicine, Inc. Organicell Regenerative Medicine, Inc.

Organicell Regenerative Medicine, Inc.

OCEL
Rank in Stocks #31539
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical... Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering biological therapies for degenerative conditions. Their primary investigational product is Zofin, an acellular biological treatment sourced from perinatal material. This therapeutic is specifically processed to preserve its inherent microRNAs, without the inclusion of any artificial additives or diluents. Zofin is currently undergoing Phase I/II clinical evaluation for its efficacy against COVID-19. Beyond its core drug development, Organicell also offers independent educational, promotional, and marketing solutions to various healthcare sectors, including medical, anti-aging, and regenerative service providers. The company maintains key research collaborations: one with the Centers for Disease Control and Prevention (CDC) to explore Zofin's anti-inflammatory and anti-infective capabilities in experimental influenza models, and another with Oklahoma State University to assess Zofin's potential in treating severe respiratory illnesses stemming from viruses with pandemic risk. Founded in 2011, this Miami, Florida-based company initially operated as Biotech Products Services and Research, Inc. It adopted its current name, Organicell Regenerative Medicine, Inc., in June 2018.
Share Price
$1.77
Last synced: 2024-04-02
Market Cap
$12.89M
Change (1 day)
-11.50%
Change (1 year)
0.00%
Country
US
Trade Organicell Regenerative Medicine, Inc. (OCEL)

Category

EPS for Organicell Regenerative Medicine, Inc. (OCEL)
EPS as of 2026 TTM: 0
According to Organicell Regenerative Medicine, Inc. latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for Organicell Regenerative Medicine, Inc. from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors